Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice

   Elevation of Brain Magnesium Reverses Memory Deficits in Alzheimer Mice

PR Newswire

HAYWARD, Calif., May 16, 2013

HAYWARD, Calif., May 16, 2013 /PRNewswire/ -- Scientists at the Center for
Learning and Memory, Tsinghua University, Beijing, and the California-based
biopharmaceutical company Magceutics, Inc. (www.magceutics.com) have
demonstrated a novel therapy for reversing memory decline in mice with
Alzheimer's Disease. By increasing brain magnesium levels, they find
significant cognitive improvement in advanced stage AD mice. The study is the
first to demonstrate a mechanism for reversing cognitive decline for advanced
stage AD mice, and is also the first to show an effective long term treatment
for early stage AD mice.

"We found that the elevation of brain magnesium can prevent cognitive decline
in Alzheimer's Disease model mice," explained Magceutics founder Guosong Liu,
a professor at Tsinghua University and senior investigator on the study. The
report, which appeared online May 8th in the Journal of Neuroscience, shows
that a newly developed magnesium compound known as Magtein™ (Magnesium-L
Threonate) can prevent cognitive impairment when administered to mice with
early stage AD. The treatment was shown to remain effective for at least 16
months. Additionally, Magtein significantly improved memory and cognition when
given to advanced stage AD mice.

Liu and colleagues believe that because the loss of neuronal connections in
brain regions critical for memory function is major hallmark of Alzheimer's
Disease, preventing those losses can lead to new treatment options. In earlier
studies, they determined the principle for controlling the density and
plasticity of connections (synapses) between neurons in the hippocampus, the
brain region that processes memory. Those studies revealed that the elevation
of brain magnesium can selectively reduce background calcium within synapses
and thereby enhance synaptic plasticity and density. Further work by Liu and
colleagues revealed that elevating magnesium can reverse memory decline in
aging rats.

The team's new study builds on those findings and sheds light on the mechanism
by which increased magnesium levels may act to protect the brain from
neurodegeneration. To explore the protective mechanism, they investigated
major signaling pathways critical for synapse function and memory formation.
They found that elevated ABeta leads to widespread activation of
calcium-dependent signaling molecules that contribute to neuronal
degeneration. The activation of these molecules dampens the activity of
proteins that are critical for synapse remodeling and memory function –
effects that the researchers discovered can be overcome with Magtein therapy.

Magceutics plans to launch a clinical trial in conjunction with Stanford
University later this year to determine whether Magtein can reverse memory
decline for human patients with Alzheimer's Disease.

Source:  "Elevation of Brain Magnesium Prevents and Reverses Cognitive
Deficits and Synaptic Loss in Alzheimer's Disease Mouse Model"  Wei Li, Jia
Yu, Yong Liu, Xiaojie Huang, Nashat Abumaria, Ying Zhu, Xian Huang, Wenxiang
Xiong, Chi Ren, Xian-Guo Liu, Dehua Chui, and Guosong Liu in Journal of
Neuroscience, 33(19), 8423-8441, published May 8, 2013.

Funding:This work was supported by grants from the National Basic Research
Program of China and the National Natural Science Foundation of China. Magtein
is patented compound owned by Magceutics, Inc (www.magceutics.com).

SOURCE Magceutics, Inc.

Website: http://www.magceutics.com
Contact: Fei Mao, Magceutics, Inc., info@magceutics.com, 510 986 4148
Press spacebar to pause and continue. Press esc to stop.